© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

CHEMOFX® DATA

  1. A Prospective Study Evaluating the Clinical Relevance of a Chemoresponse Assay for Treatment of Patients with Persistent or Recurrent Ovarian Cancer; Rutherford T, Orr Jr, J, Grendys Jr. E, Edwards R, Krivak T, Holloway R, Moore RG, Puls L, Tillmanns T, Burrell M, Hosford S, Kamat AA, Modesitt S, Schin JC, Tian C, Gabrin MJ, Brower SL, Coleman RL, Herzog TJ - Gynecologic Oncology 2013

  2. Evaluation of a Chemoresponse Assay as a Predictive Marker in the Treatment of Recurrent Ovarian Cancer; Further Analysis of a Prospective Study Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL - British Journal of Cancer 2014

  3. A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian Cancer; Krivak TC, Lele S, Richard S, Alvarez Secord A, Leath III CA, Brower SL, Tian C, Moore RG - American Journal of Obstetrics and Gynecology 2014

  4. Progression-Free Interval in Ovarian Cancer and Predictive Value of an Ex Vivo Chemoresponse Assay; Gallion HH, Christopherson WA, Coleman RL, Demars L, Herzog TJ, Hosford S, Shellhas H, Wells A, Sevin BU - International Journal of Gynecologic Cancer 2006

  5. Chemosensitivity Testing with ChemoFx and Overall Survival in Primary Ovarian Cancer; Herzog TJ, Fader AN, Fensterer JE, Gallion HH, Krivak TC, Coleman RL - American Journal of Obstetrics and Gynecology 2010

ChemoFx is Clinically Validated
ChemoFx is Medically Actionable
  1. Overview of a Chemoresponse Assay in Ovarian Cancer; Grendys EC Jr, Fiorica JV, Orr JW Jr, Holloway R, Wang D, Tian C, Chan JK, Herzog TJ - Clinical and Translational Oncology 2014

  2. In Vitro Chemoresponse to Cisplatin and Outcomes in Cervical Cancer; Grigsby P, Gan CM, Zighelboim I, Powell MA, Mutch DG, Schwarz JK - Gynecologic Oncology 2013

  3. In Vitro Chemoresponse Analysis of Cervical Cancer Patient Specimens; Grigsby PW, Gan CM, Tillmanns TD, Del Priore G - International Journal of Gynecologic Cancer 2014

  4. In Vitro Chemoresponse in Metachronous Pairs of Gynecologic Cancers; Heather J Dalton, James Fiorica, Candace K McClure, Rodney P Rocconi, Fernando O Recio, John L Levoccio, Mathew O Burrell and Bradley J Monk - Gynecologic Oncology Research and Practice 2014

  5. In Vitro Chemoresponse in Metachronous Pairs of Ovarian Cancers; Heather J Dalton, James V Fiorica, Robert P Edwards, Ivor Benjamin, Rodney P Rocconi, Fernando O Recio, John L Loveccio, Matthew O Burrell, Mark S Shahin, Edward C Grendys, Dakun Wang , Tianhua Wang and Bradley J Monk - Anticancer Research 2014

ChemoFx is Economically Beneficial
  1. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer; Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman RL - Gynecologic Oncology 2015

  2. Impact of a Chemoresponse Assay on Treatment Costs for Recurrent Ovarian Cancer; Havrilesky LJ, Krivak TC, Mucenski JW, Myers ER - American Journal of Obstetrics and Gynecology 2010

  3. In Vitro Chemoresponse in Metachronous Pairs of Ovarian Cancers; Heather J Dalton, James V Fiorica, Robert P Edwards, Ivor Benjamin, Rodney P Rocconi, Fernando O Recio, John L Loveccio, Matthew O Burrell, Mark S Shahin, Edward C Grendys, Dakun Wang , Tianhua Wang and Bradley J Monk - Anticancer Research 2014

A prospective, multi-center study (Rutherford, et al.) demonstrated improved clinical outcomes for both progression-free survival (PFS) and overall-survival (OS) in patients with recurrent ovarian cancer who were treated with a therapy that was ‘sensitive’ according to the ChemoFx assay (PFS: HR=0.67, 95% CI=0.50­0.91, p=0.009; OS: HR=0.61, 95% CI=0.41­ 0.89, p=0.010). 

These improvements amounted to median increases in PFS of 3 months (9 vs. 6 months) and OS of 14 months (38 vs. 24 months). In multivariate analysis, ChemoFx result was shown to be independently associated with PFS (HR=0.66, 95% CI=0.47­0.94, p=0.020) and OS (HR=0.59, 95% CI=0.38­0.93, p=0.023).

 

Improved clinical outcomes in patients treated with ChemoFx ‘sensitive’ therapies (as compared to patients treated with ‘non-­sensitive’ therapies) were evident in both platinum­-sensitive and platinum-­resistant sub­-populations.

 

Furthermore, 52% of tumors demonstrated in vitro sensitivity to at least one agent, suggesting that a majority of patients benefit from assay-­informed treatment selections.

PFS (A) and OS (B) in recurrent ovarian cancer patients treated with assay S (sensitive) versus I+R (Intermediate and Resistant) treatments. Patients treated with assay S treatments (n+75) experienced a median PFS of 8.8 months and median OS of 37.5 months, while those treated with assay I or R treatments (n=187) experienced a median PFS of 5.9 months and median OS of 23.9 months. Rutherford et al.